FDA grants Acurx's experimental antibiotic ACX-362E fast-track eligibility to treat Clostridium difficile infection
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, AcurxPharmaceutical sin
(http://(http:// announcedthat theAdministration of the food anddrugs (http://(
FDA(http://) has granted the experimental antibiotic ACX-362E fast channel eligibility (CDI) for the treatment of clostridium difficile infection (CDI)Prior to, the FDA also awarded ACX-362E to treat CDI's Qualified Infectious DiseaseProduct(http://(QIDP)ACX-362E
ACX-362E is a new, first-of-its-kind, oral antibiotic, the first of a new class of DNA polymerase IIIC inhibitors developed by Acurx to treat bacterial infections Currently, ACX-362E is being developed as a targeted, narrow-spectrum oral antibiotic for CDI treatment Recently, ACX-362E entered phase I clinical development and is expected to be completed in the second quarter of 2019 Acurx plans to advance agmhesination of a3CX-362E to Phase II clinical in the fourth quarter of 2019 The U.S Centers for Disease Control and Prevention (CDC) has identified C D c Co., D.C., as an urgent threat and stressed the need for new antibiotics to treat CDI
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
